Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update

Globe Newswire - Thu Aug 4, 2022

– Commercial launch of CIMERLI™ planned for early October 2022 –
– PDUFA date for toripalimab BLA is December 23, 2022 –
– Commercial preparation underway for planned July 2023 launch of YUSIMRY™ –
– UDENYCA® delivers 2^nd quarter 2022 net sales of $60.1 million –
– Conference call today at 5 p.m. ET –

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

The close: Major North American indexes rise as megacap tech stocks rally

Why this money manager is venturing back into emerging markets and adding more U.S. tech

How a Canadian pirate-clad pastor helped ignite Trump Media’s market frenzy

report on business

Activist investor targets Dye & Durham’s ‘underperformance and strategic missteps’ in letter to shareholders

The close: U.S. stocks fall as GDP report spreads rate-cut gloom; Alphabet surges 15% in post market

report on business

Fiera Capital’s largest shareholder looks to sell stake in company

The close: S&P 500 higher as markets weigh rising bond yields and upbeat U.S. earnings; TSX lower as rails slide

The close: Stocks higher as investors digest earnings